Growing attention around semaglutide vision loss has led to increased scrutiny of potential links between semaglutide medications and NAION. NAION is a type of ischemic optic neuropathy that occurs when blood flow to the optic nerve is reduced, potentially leading to sudden and sometimes permanent vision impairment. While this type of GLP-1 vision risk appears to be rare, patients should be aware of possible semaglutide vision side effects, particularly sudden or unexplained changes in eyesight.

Early symptoms of NAION are often sudden and painless, making them easy to overlook. Common signs associated with Ozempic NAION concerns include sudden vision loss in one eye, often noticed upon waking, blurred or dim vision, headache or periocular discomfort, loss of peripheral or side vision, a shadow, dark spot, or “curtain” effect and reduced color contrast or visual clarity. These symptoms may indicate optic nerve damage and should be evaluated immediately by a medical professional to rule out serious eye complications from semaglutide or other underlying causes.

The FDA has identified NAION as a potential safety signal involving GLP-1 receptor agonists, including Ozempic, and says it is evaluating the need for regulatory action.

A 2026 Diabetes Care study examining GLP-1 receptor agonists found that the relative risk was higher during the first six months of treatment and diminished with longer duration. Because that study examined the GLP-1 class rather than Ozempic alone.

NAION is generally not reversible. Vision loss caused by optic nerve damage is often permanent, although some individuals may experience partial improvement over time.

Because this form of ischemic optic neuropathy cannot typically be undone, early detection and management of contributing risk factors are critical. This includes monitoring for Ozempic vision loss symptoms and addressing vascular health conditions such as diabetes or hypertension.

Understanding your individual risk profile is key to minimizing potential GLP-1 vision risk and avoiding preventable complications. Certain individuals may be at higher risk for semaglutide/GLP-1 vision side effects or other complications. You should consult with a medical professional before using GLP-1 medications if you:

• Have a history of optic nerve conditions, including NAION
• Have diabetic retinopathy or pre-existing eye disease
• Have experienced prior episodes of sudden vision loss
• Have a personal or family history of medullary thyroid carcinoma
• Have Multiple Endocrine Neoplasia syndrome type 2 (or MEN 2)

Research and clinical literature identify underlying factors associated with NAION, and recent GLP-1 research has also investigated whether factors such as diabetes control, smoking, age, hypertension and other characteristics affect observed risk.

A 2026 study of U.S. veterans with type 2 diabetes found a higher NAION hazard among semaglutide initiators compared with SGLT2 inhibitor initiators, while another pooled analysis of randomized trials did not show increased incidence.

Semaglutide is a generic name for Ozempic.

Ozempic is manufactured by Novo Nordisk.

Rybelsus is a daily oral tablet that contains the same medication as the weekly injectable Ozempic.

Studies show that prolonged use of Ozempic may increase the risk of several side effects, but mostly notably NAION for which there is no treatment and most commonly leads to blindness.

No, if you are diagnosed with a side effect after taking Ozempic for weight loss, you may still have a claim.

If you’re experiencing symptoms associated with Ozempic vision loss or other semaglutide vision side effects, take immediate action:

• Seek urgent medical attention, especially for sudden vision loss
• Schedule a comprehensive eye exam with an ophthalmologist
• Document symptoms, including onset, severity, and affected eye
• Discuss medication risks with your prescribing provider
• Request diagnostic imaging to evaluate for optic nerve damage

Prompt intervention is essential, as conditions like can progress quickly and may lead to permanent impairment.

Seek immediate medical care if you’ve experienced:

• Sudden or painless vision loss
• A shadow, blur, or obstruction in your visual field
• Rapid changes in eyesight
• Loss of peripheral vision

These may be signs of sudden vision loss causes linked to optic nerve conditions or eye complications from semaglutide.

Consider legal consultation if:

• You’ve experienced Ozempic vision loss or were diagnosed with NAION after using semaglutide
• The condition has resulted in long-term or permanent damage
• You’ve experienced financial or quality-of-life impact